1. Search Result
Search Result
Results for "

cAMP/PKA

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

1

Screening Libraries

18

Peptides

6

Natural
Products

4

Recombinant Proteins

4

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100530C

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt
  • HY-134298

    8-(4-Chlorophenylthio)-N6-phenyl-cAMP

    PKA Others
    8-CPT-6-Phe-cAMP is an analogue of signal molecule cAMP and a potent protein kinase A (PKA) activator .
    8-CPT-6-Phe-cAMP
  • HY-100530B

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS
  • HY-110005

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS triethylamine
  • HY-131777

    Others Others
    2-Cl-cAMP is an analog of cAMP and a potent stimulator of cAMP-dependent protein kinases such as PKA type I and II. 2-Cl-cAMP can be used as starting material for cyclic nucleotides .
    2-Cl-cAMP
  • HY-B0764B

    Dibutyryl cAMP; DBcAMP

    PKA Neurological Disease
    Bucladesine (DBcAMP) is a membrane permeable selective activator that activates cyclic adenosine phosphate dependent protein kinase A (PKA). The main regulatory mechanism of Bucladesine involves the cAMP/PKA signaling pathway. When Bucladesine activates PKA, it can promote a variety of cellular processes, including neurodevelopment, growth and plasticity. In particular, the cAMP/PKA signaling pathway plays a key role in the expression of long-term enhancement (LTP) and long-term inhibition (LTD), as well as in the formation of long-term memory in the hippocampus. Bucladesine can be used to study memory formation and neuroplasticity .
    Bucladesine
  • HY-137530

    8-Methylamino-cAMP

    PKA Others
    8-MA-cAMP (8-Methylamino-cAMP) is a cyclic AMP analog that acts as a site-selective PKA agonist with similar affinity for the B site of type I and type II protein kinase A. 8-MA-cAMP is used in conjunction with priming analogs that show site A preference, such as 8-piperidinyl cAMP, to achieve selective stimulation of type I .
    8-MA-cAMP
  • HY-134263

    PKA Ras Cardiovascular Disease
    8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .
    8-Br-cAMP-AM
  • HY-137381

    N6-Benzoyl-cAMP

    Potassium Channel Others
    6-Bnz-cAMP (N6-Benzoyl-cAMP), a derivative of cyclic adenosine monophosphate (cAMP), is a potent inhibitor of the bTREK-1 potassium channel. 6-Bnz-cAMP can strongly inhibit the bTREK-1 potassium channel through a protein kinase A (PKA) independent mechanism. 6-Bnz-cAMP can be used to explore potential signal transduction proteins in the cAMP signaling pathway .
    6-Bnz-cAMP
  • HY-134308

    Fluorescent Dye Others
    8-NBD-cAMP sodium is a fluorescently labeled cyclic adenosine phosphate (cAMP) analogue. 8-NBD-cAMP sodium retains a similar biological activity to cAMP, regulating their activity by binding to specific proteins such as EPACs or PKA. 8-NBD-cAMP sodium can be used in fluorescent competitive binding experiments to evaluate the binding affinity of newly synthesized EPAC1 agonists to EPAC1 proteins .
    8-NBD-cAMP sodium
  • HY-120994

    PKA Neurological Disease Inflammation/Immunology
    Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
    Rp-8-CPT-cAMPS sodium
  • HY-120994A

    PKA Neurological Disease Inflammation/Immunology
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
    Rp-8-CPT-cAMPS
  • HY-134302

    8-Hexylamino-cAMP

    PKA Others
    8-HA-cAMP is a membrane-permeable cAMP analogue and an activator of cAMP-dependent protein kinase and PKA I. 8-HA-cAMP exerts metabolic stability towards mammalian cyclic nucleotide-responsive phosphodiesterases .
    8-HA-cAMP
  • HY-108047

    Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology
    MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .
    MK-0873
  • HY-137640B

    PKA Inflammation/Immunology Cancer
    Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion .
    Rp-8-Br-cAMPS
  • HY-137640C

    PKA Inflammation/Immunology Cancer
    Rp-8-Br-cAMPS sodium is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS sodium occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS sodium can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS sodium also inhibits insulin secretion .
    Rp-8-Br-cAMPS sodium
  • HY-103322

    PKA Cancer
    6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways .
    6-Bnz-cAMP sodium salt
  • HY-123396

    PKA Cancer
    8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity .
    8-Chloro-cAMP
  • HY-123396A

    PKA Cancer
    8-Chloro-cAMP sodium is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP sodium has anticancer activity .
    8-Chloro-cAMP sodium
  • HY-137624

    PKA Others
    Sp-cAMPS-AM is an analog of cAMP. Sp-cAMPS-AM acts as the inducer of PKA activation and CREB phosphorylation, through entrance into the cell and release of its parent polar structure Sp-cAMPS .
    Sp-cAMPS-AM
  • HY-120994B

    PKA Neurological Disease Inflammation/Immunology
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
    Sp-8-CPT-cAMPS
  • HY-134340

    8-(4-Methoxyphenylthio)-2'-O-Me-cAMP

    Ras Others Others
    8-pMeOPT-2'-O-Me-cAMP is an analogue of the signal molecule cAMP and a potent stimulator of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP does .
    8-pMeOPT-2'-O-Me-cAMP
  • HY-100530A

    PKA Neurological Disease
    Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS
  • HY-100530D
    Rp-cAMPS sodium salt
    3 Publications Verification

    PKA Neurological Disease
    Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS sodium salt
  • HY-P0248

    PKA Metabolic Disease
    Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).
    Kemptide
  • HY-100530

    PKA Neurological Disease
    Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .
    Rp-cAMPS triethylammonium salt
  • HY-P1290A
    PKA Inhibitor Fragment (6-22) amide TFA
    2 Publications Verification

    PKI-(6-22)-amide TFA

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
    PKA Inhibitor Fragment (6-22) amide TFA
  • HY-B0764A
    Bucladesine calcium
    Maximum Cited Publications
    28 Publications Verification

    Dibutyryl cAMP calcium salt; DBcAMP calcium salt

    PKA Phosphodiesterase (PDE) Apoptosis Others
    Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.
    Bucladesine calcium
  • HY-P1290

    PKI-(6-22)-amide

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
    PKA Inhibitor Fragment (6-22) amide
  • HY-131842

    N6-Benzyladenosine-3',5'-cyclic monophosphate

    PKA Cancer
    6-Bn-cAMP is a site-selective activator of cAMP-dependent protein kinase (PKA) which does not activate Epac. 6-Bn-cAMP increases hydrolytic stability against PDE, esterases, amidases and considerably higher membrane permeability compared to cAMP .
    6-Bn-cAMP
  • HY-P3930

    IP20-amide

    PKA Neurological Disease
    PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a Ki of 2.3 nM .
    PKI (5-24),amide
  • HY-12306
    8-Bromo-cAMP sodium salt
    20+ Cited Publications

    8-Br-cAMP sodium salt

    PKA Apoptosis Cancer
    8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .
    8-Bromo-cAMP sodium salt
  • HY-12306A
    8-Bromo-cAMP
    20+ Cited Publications

    8-Br-cAMP

    PKA Apoptosis Cancer
    8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .
    8-Bromo-cAMP
  • HY-134325

    8-Hydroxy-cAMP

    PKA Cardiovascular Disease Metabolic Disease
    8-OH-cAMP (8-Hydroxy-cAMP) is a polar, membrane-impermeable cyclic adenosine monophosphate analog that is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases. As a polar PKA agonist, 8-OH-cAMP is used to study the role of cAMP in the development and progression of cardiovascular and metabolic diseases .
    8-OH-cAMP
  • HY-P0291

    PKA Others
    Kemptide (Phospho-Ser5) is a phosphate acceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA).
    Kemptide Phospho-Ser5
  • HY-P3770

    PKC Others
    Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .
    Phosphate acceptor peptide
  • HY-134389

    N6-Phenyladenosine-3',5'-cyclic monophosphate

    PKA Cancer
    6-Phe-cAMP is a site-selective and highly membrane-permeant activator of protein kinase A (PKA), with a strong preference for site A of both isozymes. 6-Phe-cAMP can undergo phosphorothioate modification .
    6-Phe-cAMP
  • HY-137640

    PKA Others
    Sp-8-Br-cAMPS is an analog of cAMP(HY-B1511). Sp-8-Br-cAMPS is an agonist for cAMP, which performs a protein kinase A (PKA) activating activity with EC50 of 360 nM. Sp-8-Br-cAMPS inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .
    Sp-8-Br-cAMPS
  • HY-B0764
    Bucladesine sodium
    Maximum Cited Publications
    28 Publications Verification

    Dibutyryl cAMP sodium salt; DBcAMP sodium salt

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .
    Bucladesine sodium
  • HY-137640A

    PKA Inflammation/Immunology
    Sp-8-Br-cAMPS sodium is a cAMP analog, which performs a protein kinase A (PKA) activating activity with EC50 of 360 nM. Sp-8-Br-cAMPS sodium inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .
    Sp-8-Br-cAMPS sodium
  • HY-134264

    Ras Others Cardiovascular Disease Neurological Disease
    8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research .
    8-Br-2'-O-Me-cAMP
  • HY-B1898

    PKA Metabolic Disease
    Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.
    Metadoxine
  • HY-P1595

    PKA Metabolic Disease
    CREBtide is a CREB (cAMP response element binding protein)-like peptide. CREBtide, a synthetic 13 amino acid peptide, has been reported as a PKA substrate.
    CREBtide
  • HY-134332

    8-(4-Chlorophenylthio)-5'-AMP

    PKA PKG Others
    8-pCPT-5'-AMP is an analogue of 5'-AMP and a lipophilic activator of PKA, PKG and Epac (exchange protein activated by cAMP) .
    8-pCPT-5'-AMP
  • HY-B0764R

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine (sodium) (Standard) is the analytical standard of Bucladesine (sodium). This product is intended for research and analytical applications. Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .
    Bucladesine sodium (Standard)
  • HY-137646

    PKA Parasite Infection
    Sp-2-Cl-cAMPS is an agonist for PKA with improved membrane permeability and stability to phosphodiesterase. Sp-2-Cl-cAMPS exhibits antimalarial activity, and inhibits the proliferation of Plasmodium falciparum with an EC50 of 4 μM. Sp-2-Cl-cAMPS binds to purified P. falciparum PfPKAr (regulatory subunit of PfPKA) with a Ki of 1.3 µM .
    Sp-2-Cl-cAMPS
  • HY-136172
    ESI-08
    1 Publications Verification

    Ras Cardiovascular Disease Metabolic Disease Cancer
    ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation .
    ESI-08
  • HY-P1291
    PKI 14-22 amide,myristoylated
    1 Publications Verification

    PKA Cancer
    PKI 14-22 amide,myristoylated is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .
    PKI 14-22 amide,myristoylated
  • HY-P1595A

    PKA Metabolic Disease
    CREBtide TFA is a CREB (cAMP response element binding protein)-like peptide. CREBtide TFA a synthetic 13 amino acid peptide, has been reported as a PKA substrate .
    CREBtide TFA
  • HY-P1291A
    PKI 14-22 amide,myristoylated TFA
    1 Publications Verification

    PKA Cancer
    PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .
    PKI 14-22 amide,myristoylated TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: